Successful Tezepelumab Response and the Usefulness of Serum TARC Level as a Biomarker in a Severe Type 2 Bronchial Asthma Patient After Dupilumab, Mepolizumab, and Benralizumab Failure

Background: Treatment for severe type 2 bronchial asthma (BA) has advanced rapidly with the development of biologics. However, research on the responders and biomarkers for each biologic remains limited. Case Presentation: A 64-year-old female non-smoker with eosinophilic chronic rhinosinusitis and...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Fumihiro Kashizaki, Yu Matsumoto, Michiko Hirokado, Naomi Kawano, Ryo Ikoma
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Gleam Publishing 2024-10-01
Sarja:	Journal of Clinical Question
Aiheet:	tezepelumab thymus and activation-regulated chemokine (tarc) dupilumab mepolizumab benralizumab bronchial asthma
Linkit:	https://jclinque.com/article/successful-tezepelumab-response-and-the-usefulness-of-serum-tarc-level-as-a-biomarker-in-a-severe-type-2-bronchial-asthma-patient-after-dupilumab-mepolizumab-and-benralizumab-failure
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!